Royalty Pharma (RPRX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RPRX Royalty Pharma

Watchlist

25.730
-0.110-0.43%

Trading Jan 6 10:19 ET

11.43BMarket Cap10.13P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Looking For Yields: Comcast, Royalty Pharma And Regions Financial Are Consistent Moneymakers
Yahoo FinanceJan 2 09:01 ET
Pinning Down Royalty Pharma Plc's (NASDAQ:RPRX) P/S Is Difficult Right Now
Simply Wall StDec 26, 2024 06:42 ET
Royalty Pharma Plc (NASDAQ:RPRX) Is Favoured by Institutional Owners Who Hold 72% of the Company
Yahoo FinanceDec 24, 2024 05:35 ET
Jim Cramer Calls Royalty Pharma (RPRX) 'Disappointing' But Recommends Holding – 'I Want You To Stick With It'
Yahoo FinanceDec 24, 2024 04:45 ET
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Moomoo NewsDec 23, 2024 18:31 ET · Ratings
Royalty Pharma (RPRX) Gets a Buy From TD Cowen
TipRanksDec 23, 2024 16:15 ET · Ratings

Comments

donatello

Dec 23, 2024 11:01

🤔

$Royalty Pharma (RPRX.US)$

Trytosaveabit

Nov 4, 2024 15:05

News

$Syndax Pharmaceuticals (SNDX.US)$ $Royalty Pharma (RPRX.US)$ Press Release: Syndax Pharmaceuticals and Royalty Pharma Enter Into $350 Million Royalty Funding Agreement for Niktimvo(TM)
Dow Jones· 1 min ago

Moomoo AI

Feb 22, 2024 04:36

Unusual items boosting Royalty Pharma's profit may not recur, possibly causing a profit drop this year. The company's statutory earnings may not truly reflect its underlying earnings power. Investors should note 4 warning signs for Royalty Pharma.

There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) Earnings

Moomoo AI

Dec 18, 2023 05:24

Significant insider share selling might worry some shareholders despite the implication of the company acting in all shareholders' interest. The overall analysis of insider transactions, however, lacks confidence.